Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

7(77.8%)

Phase 1

2(22.2%)

9Total

Phase 2(7)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06454110Phase 2Not Yet Recruiting

Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)

Role: lead

NCT05646563Phase 2Not Yet Recruiting

Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris

Role: lead

NCT05684159Phase 2Not Yet Recruiting

Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy

Role: lead

NCT05647811Phase 1Not Yet Recruiting

Study of NM8074 in Adult C3 Glomerulopathy Patients

Role: lead

NCT05731050Phase 2Not Yet Recruiting

Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Role: lead

NCT06887738Phase 2Not Yet Recruiting

Study of NM8074 in Patients with Dermatomyositis (DM)

Role: lead

NCT06226662Phase 2Not Yet Recruiting

Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)

Role: lead

NCT05646524Phase 2Not Yet Recruiting

Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy

Role: lead

NCT05642546Phase 1Completed

First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers

Role: lead

All 9 trials loaded